Monitoring of controlled ovarian stimulation in IVF
DOI:10.1007/s10815-024-03182-x by Journal of Assisted Reproduction and Genetics in 2024
[1024]
TextBook
Individualised dosing of follitropin delta affects live birth and safety in IVF: an individual participant data meta-analysis of randomised controlled trials
DOI:10.1016/j.fertnstert.2024.05.143 by Fertility and Sterility in 2024
[854]
Efficacy and safety of follitropin delta versus follitropin alpha/beta in infertility treatment: A systematic review and meta-analysis
DOI:10.1002/rmb2.12573 by Reproductive Medicine and Biology in 2024
[797]
Using GnRH agonists in combination with hCG in antagonist ART cycles: A SCOPING Review of recent evidences
DOI:https://www.jbra.com.br/media/html/JBRA2377.html by JBRA Assisted Reproduction in 2023
[562]
Progestin primed ovarian stimulation, for whom, when and how?
DOI:/10.1016/j.rbmo.2023.103639 by Reproductive BioMedicine Online in 2023
[497]
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
DOI:10.1002/14651858.CD005070.pub3 by Cochrane Database Syst Rev. in 2017
[166]
Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
DOI:10.1002/14651858.CD005289.pub4 by Cochrane Database Syst Rev. in 2021
[165]
Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
DOI:10.1186/s12958-021-00759-4 by Reproductive Biology and Endocrinology in 2021
[137]
Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis.
DOI:10.1016/j.rbmo.2021.12.006 by Reproductive BioMedicine Online in 0
[91]
Recent Publications
Ovarian Stimulation Effects on Ghrelin Secretion and Reproductive Potential
DOI:10.1111/cen.15167 by Clinical Endocrinology in 2024
[2317]
Adjuvant letrozole administration in gonadotropin releasing hormone antagonist cycles do not affect ploidy status of embryos
DOI:10.1016/j.jogoh.2023.102689 by Journal of Gynecology Obstetrics and Human Reproduction in 2024
[2251]
Impact of letrozole co-treatment in an antagonist protocol for IVF/ICSI: a retrospective study
DOI:10.1186/s12958-024-01297-5 by Reproductive Biology and Endocrinology in 2024
[2153]
From patient classification to optimized treatment in ART: the AMPLITUDE Delphi consensus
DOI:10.3389/frph.2024.1467322 by Frontiers in Reproductive Health in 2024
[2137]
Impact of GnRH antagonist pretreatment on oocyte yield after ovarian stimulation: A retrospective analysis
DOI:10.1371/journal.pone.0308666 by PLoS One. in 2024
[2131]
Dual trigger or hCG alone: A retrospective analysis on patients with diminished ovarian reserve under in vitro fertilization and embryo transfer (IVF-ET) treatment
DOI:10.1016/j.ejogrb.2024.09.039 by European Journal of Obstetrics & Gynecology and Reproductive Biology in 2024
[2097]
The Additive Effect of Combinations of FSH Receptor Gene Variants in Ovarian Response to Stimulation
DOI:10.1007/s43032-024-01700-x by Reproductive Science in 2024
[2024]
Programing the onset of ovarian stimulation: From early follicular phase start to oral contraceptive (OC) pill, to luteal phase E2, Duo-Stim and random start OS protocols
DOI:10.1016/j.fertnstert.2024.09.011 by Fertility and Sterility in 2024
[1941]
Letrozole co-treatment in an antagonist protocol for overweight women undergoing IVF treatment: a retrospective study
DOI:10.1186/s12884-024-06795-3 by BMC Pregnancy and Childbirth in 2024
[1916]
DuoStim: do we have enough evidence to use it?
DOI:10.1016/j.fertnstert.2024.08.333 by Fertility and Sterility in 2024
[1915]
Luteinizing hormone supplementation with human menopausal gonadotropin versus low dose human chorionic gonadotropin during ovarian stimulation does not affect live birth rates after fresh and frozen embryo transfer
DOI:10.1111/jog.16065 by Journal of Obstetrics and Gynaecology Research in 2024
[1897]
GnRH agonist-only trigger, compared to dual trigger, reduces oocyte retrieval rate in high responders without affecting cumulative live birth rate
DOI:10.3389/fendo.2024.1461317 by Frontiers in Endocrinology (Lausanne) in 2024
[1864]
Exposure of antral follicles to medroxyprogesterone acetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles
DOI:10.1093/humrep/deae189 by Human Reproduction in 2024
[1773]
Effect of LH level on HCG trigger day on clinical outcomes in patients with diminished ovarian reserve undergoing GnRH-antagonist protocol
DOI:10.1186/s12958-024-01280-0 by Reproductive Biology and Endocrinology in 2024
[1765]
Unexpected poor oocyte retrieval: The phenomenon of the borderline response to the Gonadotropin Releasing Hormone (GnRH) agonist trigger
DOI:10.1016/j.xfre.2024.08.001 by F&S Reports, in 2024
[1749]
Economic evaluation of GnRH-agonist long protocol and GnRH-antagonist protocol in IVT/ICSI among the Chinese population: using pharmacoeconomic models
DOI:10.1136/bmjopen-2023-079715 by BMJ Open. in 2024
[1711]
Extended versus conventional letrozole regimen in patients with polycystic ovary syndrome undergoing their first ovulation induction cycle: a prospective randomized controlled trial
DOI:10.1093/hropen/hoae046 by Human Reproduction Open in 2024
[1605]
The good, the bad and the ugly of luteal phase stimulations
DOI:10.1016/j.rbmo.2024.104383 by Reproductive BioMedicine Online in 2024
[1542]
Comparison of Adding Sildenafil Versus Estradiol to Clomiphene Citrate on the Applebaum Score and Pregnancy Rate in Patients With Unexplained Infertility: A Double-Blind Randomized Controlled Trial
DOI:10.7759/cureus.63414 by Cureus. in 2024
[1532]
Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial
DOI:10.22074/ijfs.2023.2008905.1513 by International Journal of Fertility & Sterility in 2024
[1468]
Undetected, natural conception pregnancies in luteal phase stimulations—case series and review of literature
DOI:10.1093/humrep/deae165 by Human Reproduction in 2024
[1420]
Reproductive Outcomes of Dual Trigger versus hCG Alone in Women Undergoing In Vitro Fertilization with Fresh Embryo Transfer Cycles
DOI:10.1155/2024/9972437 by Obstetrics and Gynecology International in 2024
[1412]
Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial
DOI:10.1093/humrep/deae167 by Human Reproduction in 2024
[1406]
Gonadotropin-Releasing Hormone (GnRH) Agonist Protocol Improves Pregnancy Outcomes During In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatment in Young Infertile Women: A Retrospective Study
DOI:10.7759/cureus.61554 by Cureus. in 2024
[1310]
Monitoring of controlled ovarian stimulation in IVF
DOI:10.1007/s10815-024-03182-x by Journal of Assisted Reproduction and Genetics in 2024
[1302]
Co-administration of GnRH-agonist and hCG (double trigger) for final oocyte maturation increases the number of top-quality embryos in patients undergoing IVF/ICSI cycles
DOI:10.1186/s13048-024-01465-6 by Journal of Ovarian Research in 2024
[1295]
Feasibility and efficacy of a subcutaneous catheter for controlled ovarian stimulation
DOI:10.1016/j.fertnstert.2024.06.022 by Fertility and Sterility in 2024
[1282]
Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study
DOI:10.3389/fendo.2024.1358278 by Frontiers in Endocrinology (Lausanne) in 2024
[1275]
Metagenomic analysis revealed the association between gut microbiota and different ovary responses to controlled ovarian stimulation
DOI:10.1038/s41598-024-65869-6 by Scientific Reports in 2024
[1248]
A modified flexible GnRH antagonist protocol using antagonist early cessation and a gonadotropin step-down approach improves live birth rates in fresh cycles: a randomized controlled trial
DOI:10.1093/humrep/deae145 by Human Reproduction in 2024
[1246]
GnRH agonist early follicular challenge test as a predictor of ovarian response in antagonist cycles for fertility preservation
DOI:10.1038/s41598-024-65059-4 by Scientific Reports in 2024
[1201]
What protocol should not be adopted, and which patients should not be suggested double stimulation in the same ovarian cycle? A randomized controlled trial answers
DOI:10.1093/humrep/deae141 by Human Reproduction in 2024
[1180]
BEYOND Investigators , BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle,
DOI:10.1093/humrep/deae092 by Human Reproduction in 2024
[994]
Webinars
Progestin primed ovarian stimulation: for whom, when and how? An interview with Baris Ata
RBMO Live
New strategies to optimize ovarian stimulation for IVF/ICSI: a window to the future [IVFWW]
IVF WorldWide
Progestin Primed Ovarian Stimulation [IVFWW]
IVF WorldWide
Sub topics related to :Ovarian stimulation.
ID
Course
Add-on treatment options and ART
References related to SubTopic
Madina Sarwari, Kiri Beilby, Karin Hammarberg, Martha Hickey, Sarah Lensen. Endometrial scratching in Australia, New Zealand and the United Kingdom (UK): a follow-up survey. Human Fertility, 2021, 1 DOI: 10.1080/14647273.2021.1995902 - ID:4095
Taylor & Francis Group. "Third of fertility specialists still recommend a type of IVF treatment which has no clear evidence of benefit." ScienceDaily. ScienceDaily, 14 December 2021. http://www.sciencedaily.com/releases/2021/12/211214200532.htm - ID:4096
Glatthorn HN, Decherney A. The efficacy of add-ons: selected IVF "add-on" procedures and future directions. J Assist Reprod Genet. 2022 Jan 23. doi: 10.1007/s10815-022-02410-6 - ID:4197
Armstrong S, Atkinson M, MacKenzie J, Pacey A, Farquhar C. Add-ons in the laboratory: hopeful, but not always helpful. Fertil Steril. 2019 Dec,112(6):994-999. doi: 10.1016/j.fertnstert.2019.10.031 - ID:4198
Human Fertilization and Embryology Authority
Treatment add-ons 2018. https://www.hfea.gov.uk/treatments/treatment-add-ons/ - ID:4261
Iacoponi O, van de Wiel L, Wilkinson J, Harper JC. Passion, pressure and pragmatism: how fertility clinic medical directors view IVF add-ons. Reprod Biomed Online. 2022 Mar 4:S1472-6483(22)00131-6. doi: 10.1016/j.rbmo.2022.02.021 - ID:4405
Macklon NS, Ahuja KK, Fauser B. Building an evidence base for IVF 'add-ons'. Reprod Biomed Online. 2019 Jun,38(6):853-856. doi: 10.1016/j.rbmo.2019.04.005 - ID:4406
Harper J, Jackson E, Sermon K, Aitken RJ, Harbottle S, Mocanu E, Hardarson T, Mathur R, Viville S, Vail A, Lundin K. Adjuncts in the IVF laboratory: where is the evidence for 'add-on' interventions? Hum Reprod. 2017 Mar 1,32(3):485-491. doi: 10.1093/humrep/dex004 - ID:4407
Zemyarska MS. Is it ethical to provide IVF add-ons when there is no evidence of a benefit if the patient requests it? J Med Ethics. 2019 May,45(5):346-350. doi: 10.1136/medethics-2018-104983 - ID:4408
